STAT June 6, 2024
Allison DeAngelis, Adam Feuerstein

How did advisers react to the first psychedelic therapy to go before the Food and Drug Administration? And did the American Society of Clinical Oncology meeting surpass expectations?

We discuss that and more in this week’s episode of “The Readout LOUD.” STAT colleague Meghana Keshavan joins us to dissect Lykos Therapeutics’ meeting with an FDA advisory committee. We also discuss the latest news in the health and life sciences, including stories from major...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

Continue Reading

 
Topics: Biotechnology, Conferences / Podcast, FDA, Govt Agencies, Pharma, Pharma / Biotech, Trends
Related Articles:
Anna Greka: Molecular Sleuthing for Rare Diseases
The Weapons of Getting Paid: Bringing Data, Technology, and Advocacy to the Battle
Will Trump Drug Tariffs Help Or Hurt The U.S.?
Johnson & Johnson Discontinues Pivotal Depression Drug Trial Due to Lack of Efficacy
Walgreens To Be Acquired By PE Firm Sycamore Partners Amid Shift In Health Care Strategy

Share This Article